Desloratadine 5mg 10 tablets

$16.00

Desloratadine 5mg 10 tablets

Free Shipping

Produced in Ukraine

 

Description

Desloratadine 5mg 10 tablets

 

Pharmacological group: Antihistamines for systemic use. Code АТХ R06A X27.

Composition:

Active ingredient: desloratadine;

1 coated tablet contains 5 mg desloratadine; excipients: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, corn starch, talc, carnauba wax, white wax, lactose monohydrate, hypromellose, titanium dioxide (E 171), polyethylene glycol, indigo carmine (E 132).

Indications:

Elimination of symptoms associated with: allergic rhinitis; hives.

Pharmacodynamics:

Desloratadine is a long-acting non-sedative antihistamine that selectively antagonizes peripheral H1 receptors. After oral administration, the drug selectively blocks peripheral histamine H1 receptors.

In in vitro studies, the drug has demonstrated its anti-allergic and anti-inflammatory properties on endothelial cells. This was manifested by inhibition of the release of anti-inflammatory cytokines, such as IL-4, IL-6, IL-8, and IL-13, from human mast cells / basophils, as well as inhibition of the expression of adhesion molecules such as P-selectin. The clinical significance of these observations still needs confirmation. In clinical studies of high doses, in which desloratadine was administered daily at a dose of up to 20 mg for 14 days, statistically significant changes in the cardiovascular system were not observed. In a clinical pharmacological study, when using 45 mg per day (10 times the maximum daily clinical dose) for 10 days, no prolongation of the QT interval was observed.

In patients with allergic rhinitis, desloratadine effectively eliminated symptoms such as sneezing, nasal discharge and itching, as well as eye irritation, watery eyes and redness, and itching of the palate. Desloratadine effectively controlled symptoms for 24 hours. The drug almost does not penetrate the central nervous system (CNS). In controlled clinical trials, when taken at the recommended dose of 5 mg per day, the incidence of drowsiness did not differ from the placebo group. In clinical studies, a single dose of the drug in a daily dose of 7.5 mg did not affect psychomotor activity.

Desloratadine effectively alleviates the severity of the course of seasonal allergic rhinitis, taking into account the total indicator of the questionnaire on assessing the quality of life in rhinoconjunctivitis. The greatest improvement was noted on the items on the questionnaire related to practical problems and daily activities that were limited by symptoms. Chronic idiopathic urticaria was studied in a clinical model with urticaria conditions. Since the release of histamine is a causative factor in all forms of urticaria, desloratadine is expected to be effective in relieving symptoms in forms of urticaria other than chronic idiopathic urticaria.

In two placebo-controlled 6-week studies in patients with chronic idiopathic urticaria, desloratadine effectively relieved pruritus and reduced the number and size of urticaria until the end of the first dosing interval. In each study, the effect lasted over a 24 hour dosing interval. Itching relief of more than 50% was seen in 55% of patients taking desloratadine compared with 19% of patients taking placebo. Taking the drug does not show a significant effect on sleep and daytime activity.

Contraindications:

Increased individual sensitivity to desloratadine, loratadine and to any component of the drug.

Method of administration and dosage:

The drug is taken orally.

Adults and children over 12 years of age take 1 tablet (5 mg) 1 time per day, regardless of food intake, to eliminate symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria. Therapy for intermittent allergic rhinitis (the presence of symptoms less than 4 days a week or less than 4 weeks) should be carried out taking into account the history data: stop after the disappearance of symptoms and resume after their recurrence. For persistent allergic rhinitis (symptoms of more than 4 days a week or more than 4 weeks), treatment should be continued during the entire period of exposure to the allergen.

Children:

There are limited data from clinical studies of the effectiveness of desloratadine tablets in adolescents from 12 to 17 years old (see section “Adverse Reactions”). The effectiveness and safety of the drug for children under 12 years of age have not been established. For children from 12 years old, the use of the drug is possible after consulting a doctor.

 

Shelf life:
2 years.

Storage conditions:
Store in its original packaging at a temperature not exceeding 25 °C.

Produced in Ukraine